Cholestyramine
- Generic Name
- Cholestyramine
- Brand Names
- Prevalite, Questran
- Drug Type
- Small Molecule
- Chemical Formula
- -
- CAS Number
- 11041-12-6
- Unique Ingredient Identifier
- 4B33BGI082
- Background
Cholestyramine or colestyramine is a bile acid sequestrant. Bile acid sequestrants are polymeric compounds which serve as ion exchange resins. Cholestyramine resin is quite hydrophilic, but insoluble in water.
- Indication
Indicated as adjunctive therapy to diet for the reduction of elevated serum cholesterol in patients with primary hypercholesterolemia (elevated low density lipoprotein [LDL] cholesterol) who do not respond adequately to diet. Also for the relief of pruritus associated with partial biliary obstruction.
- Associated Conditions
- Atherosclerosis, Primary Hypercholesterolemia, Pruritus
- Associated Therapies
- -
Gemcitabine and Leflunomide in Patients With Advanced Unresectable Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-06-12
- Last Posted Date
- 2024-06-12
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 19
- Registration Number
- NCT06454383
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis
- First Posted Date
- 2023-11-21
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 1400
- Registration Number
- NCT06141473
- Locations
- 🇺🇸
University of Alabama at Birmingham- Site Number : 8401135, Birmingham, Alabama, United States
🇺🇸North Central Neurology Associates- Site Number : 8401100, Cullman, Alabama, United States
🇺🇸St. Joseph's Hospital and Medical Center- Site Number : 8401139, Phoenix, Arizona, United States
A Study to Evaluate the Effect of Cholestyramine on LOXO-783 in Healthy Participants
- First Posted Date
- 2023-06-08
- Last Posted Date
- 2023-09-26
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 21
- Registration Number
- NCT05894928
- Locations
- 🇺🇸
Labcorp Clinical Research Unit, Dallas, Texas, United States
Leflunomide in Combination With Steroids for the Treatment of Acute Graft-versus-Host Disease After Donor Stem Cell Transplant for Hematologic Malignancies
- Conditions
- Interventions
- First Posted Date
- 2022-07-05
- Last Posted Date
- 2024-06-21
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 18
- Registration Number
- NCT05443425
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma in African-American and European-American Patients
- Conditions
- Interventions
- First Posted Date
- 2021-08-20
- Last Posted Date
- 2024-05-31
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 56
- Registration Number
- NCT05014646
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
🇺🇸Wayne State University/Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
A Clinical Study to Assess the Effect of Change of Bile Acid on the PD and Safety of Metformin and Microbiome Profiles
- First Posted Date
- 2020-04-06
- Last Posted Date
- 2021-03-17
- Lead Sponsor
- Seoul National University Hospital
- Target Recruit Count
- 15
- Registration Number
- NCT04335526
- Locations
- 🇰🇷
Seoul National University Bundang Hospital, Seoul, Korea, Republic of
An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia
- Conditions
- Interventions
- First Posted Date
- 2018-04-27
- Last Posted Date
- 2023-05-06
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 153
- Registration Number
- NCT03510884
- Locations
- 🇪🇸
Investigational Site Number :7240003, Pamplona, Navarra, Spain
🇵🇱Investigational Site Number :6160002, Gdansk, Pomorskie, Poland
🇲🇽Investigational Site Number :4840007, Oaxaca, Mexico
An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Homozygous Familial Hypercholesterolemia
- First Posted Date
- 2018-04-27
- Last Posted Date
- 2020-12-29
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 18
- Registration Number
- NCT03510715
- Locations
- 🇩🇰
Investigational Site Number 2080001, Viborg, Denmark
🇪🇸Investigational Site Number 7240001, A Coruna, Spain
🇸🇮Investigational Site Number 7050001, Ljubljana, Slovenia
A Safety and Pharmakokinetic Study of A4250 Alone or in Combination With A3384
- First Posted Date
- 2016-11-15
- Last Posted Date
- 2024-03-07
- Lead Sponsor
- Albireo
- Target Recruit Count
- 94
- Registration Number
- NCT02963077
An 8-Week Dose-Finding Study to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia
- First Posted Date
- 2016-09-07
- Last Posted Date
- 2019-09-06
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 42
- Registration Number
- NCT02890992
- Locations
- 🇨🇿
Investigational Site Number 2030002, Zlin, Czechia
🇺🇸Investigational Site Number 8400005, Charlotte, North Carolina, United States
🇺🇸Investigational Site Number 8400001, Cincinnati, Ohio, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.